Loading…
← CockpitCompetitor Analysis › 300199.SZ Hybio Pharmaceutical Co., Ltd. Class AOpen in the cockpit ↗

Hybio Pharmaceutical Co., Ltd. Class A300199.SZCompetitor analysis, valuation and peers

China · CNY·Health Care›Pharmaceuticals: Major

Chinese maker of peptide (polypeptide) active pharmaceutical ingredients and formulations.

Momentum neutral 55
Mkt cap
$2.68B
US dollars, full cap
Free float
96%
of shares outstanding
$/day
$140M
20-day average traded
Fwd P/E
44.7×
forward earnings
ROIC−WACC
+1.2 pp
WACC 14.0%
Hurdle
+31 pp
Req g minus delivered
Next earnings
162 days
29 Apr 2027
Close · CNYCN¥21.49
1D-3.2%
1W-8.6%
1M-18.9%
3M-19.0%
6M-8.0%
YTD+20.1%
1Y+2.2%
ATR %5.8%
52w lowhigh22.4% off high

What Hybio Pharmaceutical does

Chinese maker of peptide (polypeptide) active pharmaceutical ingredients and formulations.

Products and services

  • Peptide APIs
  • Peptide drug formulations

Customers

  • Pharma companies (API buyers)
  • Hospitals (own formulations)

Where it sits in the supply chain

  • Health Care
  • Pharmaceuticals
  • Peptide API manufacturing

What could go right

  • GLP-1/peptide drug demand growth

What could go wrong

  • API price competition

Moat: narrow (process know-how). Specialized peptide-synthesis manufacturing know-how versus small-molecule generic makers.

Headquarters: Shenzhen, China · Employees: 1,226

Named competitors

Hybio Pharmaceutical at a glance

Size Hybio Pharmaceutical (300199.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $2.68B, the 883rd largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥21.49 on 18 Nov 2026.

Performance Over six months the shares fell 8.0%, against -11.8% for the median peer and -20.0% for the China market (cap-weighted) — 9th highest of 21 in its peer set.

Growth Revenue grew 70.2% over the last twelve months (peer median +2.6%); the operating margin is 31.4% (peer median 9.3%).

Valuation It trades at 44.7× forward earnings against a peer median of 24.2× (5th most expensive of 17).

Price implies For today's price to make sense, revenue must grow about 37% a year for seven years (Req g). Recent delivered growth is +6%, so the hurdle is +31 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 1.2 points above its cost of capital (14.0% WACC).

Next results Next results expected around 29 Apr 2027 (exchange calendar; dates can move).

Relative performance

809010011021 May 202621 Aug 202618 Nov 2026Peer median 89300199.SZ 88
Six months, rebased to 100: Hybio Pharmaceutical against the median of its 20 peers (local-currency closes).

Hybio Pharmaceutical financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥1.53BCN¥963MCN¥590MCN¥419MCN¥688M
Revenue growth—+63%+41%-39%—
Gross profitCN¥1.03BCN¥496MCN¥264MCN¥131MCN¥467M
EBITDAn/aCN¥305MCN¥110M-CN¥223M-CN¥42.2M
Net incomeCN¥402MCN¥36.6M-CN¥174M-CN¥514M-CN¥371M
Free cash flowCN¥17.1MCN¥2.84MCN¥54.1M-CN¥85.3M-CN¥173M
Capital expenditureCN¥327MCN¥234MCN¥116MCN¥81.8MCN¥190M
Total debtCN¥2.05BCN¥1.92BCN¥1.80BCN¥2.00BCN¥1.80B

Quarterly statements and history in the cockpit →

Hybio Pharmaceutical competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%-25%0%+25%+50%-20%0%300558BIOA-B600518IDYA600380301301ALMNEULANDLAB0867002773VCELPBH369621620013NAMS0002502696PRGOACAD300199.SZ6-month return →1-month return →
Up and to the right = strong over both horizons. Hybio Pharmaceutical is the large dot.

Fundamentals: revenue growth against valuation

-50%0%+50%+100%+150%25×50×75×300558BIOA-B600380301301ALMNEULANDLAB0867002773VCELPBH369600132696PRGOACAD300199.SZRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Hybio Pharmaceutical is the large dot.

Capital: growth delivered against growth the price implies

0%+50%+100%0%50%100%300558BIOA-B600380301301ALM0867VCEL36962696PRGOACAD300199.SZGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Hybio Pharmaceutical is the large dot.

Hybio Pharmaceutical competitors and peer comparison

Head to head with its named competitors (300199.SZ vs BANB.SW vs PPGN.SW)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Hybio Pharmaceutical 300199.SZ$2.68B-8%+70%31%44.7×37.4%
Bachem BANB.SW$7.06B0%+5%19%32.4×n/a
PolyPeptide PPGN.SW$1.61B+7%+22%7%52.1×n/a

How Hybio Pharmaceutical compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Hybio Pharmaceutical against its 20 peers (data as of 18 Nov 2026)
Measure300199.SZPeer medianRank in peer set
1-month return-18.9%-3.6%4th lowest of 21
6-month return-8.0%-11.8%9th highest of 21
Distance from 52-week high-22.4%-38.0%7th highest of 21
Revenue growth (TTM)+70.2%+2.6%2nd highest of 21
Operating margin31.4%9.3%highest of 21
Forward P/E44.7×24.2×5th most expensive of 17
Growth the price implies (Req g, 7 yrs)37.4%11.7%4th most demanding of 15
Growth delivered (Del g)+6.1%+10.5%6th lowest of 15
Hurdle (Req g minus delivered)+31.2 pp-1.0 ppmost demanding of 15
ROIC minus cost of capital+1.2 pp-0.9 pp7th highest of 17

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Hybio Pharmaceutical 300199.SZChina$2.68B-8%+70%31%44.7×37.4%+6.1%
Betta Pharmaceuticals 300558.SZChina$2.70B-15%+16%11%38.0×23.2%+14.0%
BioArctic BIOA-B.STSweden$2.66B-9%-46%22%52.9×25.5%+100.1%
Kangmei Pharmaceutical 600518.SSChina$2.61B-21%-6%-7%n/an/an/a
IDEAYA Biosciences IDYAUnited States$2.56B-11%-83%-1,267%n/an/an/a
Joincare Pharmaceutical Group Industry 600380.SSChina$2.85B0%-12%18%15.5×-13.1%+2.4%
Yili Chuanning Biotechnology 301301.SZChina$2.49B-24%-14%16%27.6×3.4%+4.8%
Almirall ALM.MCSpain$2.46B-13%+24%8%27.1×6.1%+6.5%
Neuland Laboratories NEULANDLAB.NSIndia$2.95B+28%+50%26%63.4×n/an/a
China Medical System 0867.HKHong Kong$2.95B-15%+15%20%9.8×1.1%+2.7%
Chengdu Kanghong Pharmaceutical 002773.SZChina$2.99B-1%-11%24%20.1×-3.3%+7.0%
Vericel VCELUnited States$2.99B+66%+25%8%68.3×46.5%+17.3%
Prestige Consumer Healthcare PBHUnited States$2.40B+7%+5%25%10.6×2.3%+2.9%
InSilico Medicine Cayman TopCo 3696.HKHong Kong$2.40B-33%+153%-7%85.2×37.9%+22.9%
Keymed Biosciences 2162.HKHong Kong$2.39B+7%0%-73%18.2×n/an/a
HUTCHMED (China) 0013.HKHong Kong$2.38B+14%-9%-6%35.9×47.0%+19.3%
NewAmsterdam Pharma NAMSUnited States$2.37B-45%-26%-900%n/an/an/a
Sam Chun Dang Pharm 000250.KSSouth Korea$2.36B-66%+23%7%n/an/an/a
Shanghai Henlius Biotech 2696.HKHong Kong$3.05B-39%+33%12%21.3×14.1%+61.4%
Perrigo PRGOUnited States$2.35B+52%-4%5%6.7×14.1%+0.8%
ACADIA Pharmaceuticals ACADUnited States$3.08B-15%+15%10%17.8×9.2%+19.4%

Questions

Who are Hybio Pharmaceutical's main competitors?
Named competitors: Bachem (BANB.SW), PolyPeptide Group (PPGN.SW). The cockpit's measured peer set (industry) also includes Betta Pharmaceuticals (300558.SZ), BioArctic (BIOA-B.ST), Kangmei Pharmaceutical (600518.SS), IDEAYA Biosciences (IDYA), Joincare Pharmaceutical Group Industry (600380.SS), Yili Chuanning Biotechnology (301301.SZ).
Is Hybio Pharmaceutical expensive compared with its peers?
On forward p/e it trades at 44.7× against a peer median of 24.2×, 5th most expensive of 17 in its peer set. For today's price to make sense, revenue must grow about 37% a year for seven years (Req g). Recent delivered growth is +6%, so the hurdle is +31 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Hybio Pharmaceutical stock performed?
Over six months to 18 Nov 2026 the shares returned -8.0% against -11.8% for the median peer; over one year +2.2%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.